PDCD1 and neoplasm: Similarly, a phase 2 clinical trial (NCT02406781) showed that PD-1 inhibition alone was not sufficient to control tumour growth and that a combination of inhibition of the colony stimulating factor 1 receptor and the IDO pathway resulted in more effective tumour control (12).